Since salt intake may affect blood pressure response to antihypertensi
ve drugs, an individual's salt-sensitivity status may be an important
consideration in the selection of a medication. The purpose of this si
ngle-blind study was to assess the impact of salt sensitivity on the a
ntihypertensive effects of isradipine. A total of 21 evaluable hyperte
nsive patients (10 white, 11 black) 35 to 73 years of age (mean 55.9 y
ears) were randomized to a low-salt diet (mean 24-hour urine sodium 10
0+/-14 mmol) or a high-salt diet (mean 24-hour urine sodium 210+/-22 m
mol) for 7 weeks, followed by crossover to the other diet after a 2-we
ek washout period. On each diet regimen, patients received placebo for
2 weeks, followed by optimal titration of isradipine (2.5 to 10 mg BI
D) for blood pressure control during the last 5 weeks. On the high-sal
t diet, salt-sensitive hypertensives (mean arterial blood pressure inc
rease greater than or equal to 5 mm Hg, n=5) exhibited a systolic/dias
tolic blood pressure change of -18.7/-19.6 mm Hg from 157.2/102.9 mm H
g after 5 weeks of isradipine treatment: whereas on a low-salt diet, b
lood pressure change was -6.9/-12.0 mm Hg from 148.7/97.3 mm Hg. Non-s
alt-sensitive patients (n=16) exhibited a systolic/diastolic blood pre
ssure change of -12.6/-7.6 mm Hg from 155.3/98.6 mm Hg on the high-sal
t diet and -19.2/-10.9 mm Hg from 161.6/102.6 mm Hg on the low-salt di
et after treatment with isradipine. The absolute blood pressure attain
ed in both salt-sensitive and non-salt-sensitive patients was almost i
dentical with isradipine therapy despite variation in dietary salt, al
though slightly higher doses of isradipine were required in the salt-s
ensitive group. Consequently: isradipine, and perhaps calcium antagoni
sts in general, manifests a more robust blood pressure-lowering effect
in the setting of high sodium intake. This effect does, however, appe
ar to be largely confined to individuals who are salt sensitive.